These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16284715)

  • 1. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies.
    Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Kalofonos HP; Chroni E
    J Neurol; 2005 Dec; 252(12):1459-64. PubMed ID: 16284715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy.
    Argyriou AA; Polychronopoulos P; Koutras A; Xiros N; Petsas T; Argyriou K; Kalofonos HP; Chroni E
    Eur J Cancer Care (Engl); 2007 May; 16(3):231-7. PubMed ID: 17508942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
    Argyriou AA; Polychronopoulos P; Koutras A; Iconomou G; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
    Support Care Cancer; 2006 Mar; 14(3):223-9. PubMed ID: 16021477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings.
    Augusto C; Pietro M; Cinzia M; Sergio C; Sara C; Luca G; Scaioli V
    J Neurooncol; 2008 Jan; 86(1):89-99. PubMed ID: 17611715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?
    Argyriou AA; Polychronopoulos P; Koutras A; Iconomou G; Iconomou A; Kalofonos HP; Chroni E
    Support Care Cancer; 2005 Aug; 13(8):647-51. PubMed ID: 15711945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
    Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.
    Berger T; Malayeri R; Doppelbauer A; Krajnik G; Huber H; Auff E; Pirker R
    Eur J Cancer; 1997 Aug; 33(9):1393-9. PubMed ID: 9337680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
    Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M
    Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation.
    Osmani K; Vignes S; Aissi M; Wade F; Milani P; Lévy BI; Kubis N
    J Neurol; 2012 Sep; 259(9):1936-43. PubMed ID: 22349867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy.
    Magnowska M; Iżycka N; Kapoła-Czyż J; Romała A; Lorek J; Spaczyński M; Nowak-Markwitz E
    Ginekol Pol; 2018; 89(4):200-4. PubMed ID: 29781075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
    Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
    Chaudhry V; Rowinsky EK; Sartorius SE; Donehower RC; Cornblath DR
    Ann Neurol; 1994 Mar; 35(3):304-11. PubMed ID: 7907208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
    Leandro-García LJ; Inglada-Pérez L; Pita G; Hjerpe E; Leskelä S; Jara C; Mielgo X; González-Neira A; Robledo M; Avall-Lundqvist E; Gréen H; Rodríguez-Antona C
    J Med Genet; 2013 Sep; 50(9):599-605. PubMed ID: 23776197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):55-8. PubMed ID: 11206272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
    Lee CK; Gurney H; Brown C; Sorio R; Donadello N; Tulunay G; Meier W; Bacon M; Maenpaa J; Petru E; Reed N; Gebski V; Pujade-Lauraine E; Lord S; Simes RJ; Friedlander M
    Br J Cancer; 2011 Jul; 105(3):360-5. PubMed ID: 21750553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
    Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
    Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
    J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.